Arcturus Therapeutics Ltd (ARCT.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|75||2018||Chairman of the Board|
|46||2018||President, Chief Executive Officer, Director|
|52||2018||Interim Chief Financial Officer, Director|
|2018||Chief Operating Officer, Chief Scientific Officer|
- BRIEF-Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeutics
- BRIEF-Joseph Payne Says "Rejects" Arcturus Therapeutics' Board Of Directors' Latest Lawsuit Against Payne
- BRIEF-Arcturus Therapeutics Files Lawsuit Against Former CEO Joseph Payne And His Associates
- BRIEF-Joseph Payne Sent Letter To Arcturus Board To Restate Prior Demand To Convene EGM
- BRIEF-Joseph Payne Says Calling On Arcturus Therapeutics' Board To Hold EGM "Without Further Delay"